Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Olpasiran reduces oxidized phospholipids but not inflammation in cardiovascular disease—what does this mean for clinical care ...